HannahN1512 Updated   
NASDAQ:VIR   Vir Biotechnology, Inc.
The VIR weekly chart shows an obvious resemblance between Phase 1 and Phase 2, so we can expect a breakout to $80-90 zone on good news, for example Q4 Earning report with Covid treatmengt Sotrovimab sales worldwide or good trial readouts from their developing products, when the Phase 2 completed.

Note: VIR share price is heavily undervalued, the fair share value is $46. The company has good recent ERs. They have 1 billion in cash, no debt.

Buy zone: $30-35, enter now after the last fall on the news on Pfizer's pill, but it will go through ups and downs before the possible spike or wait until Waves F, G completed (which is safer but you can miss the spike if you enter too late)

Price Target: $80-85 in three months

My ideas can be 100% wrong, please do your own DDs before entering a position with VIR or any other stocks

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
Good news for VIR today! The US government has just secured 1 billion contract with VIR on Sotrovimap. The Q4 ER in February must be excellent!

The breakout has started earlier than I expected due to the fear of the Omicron variant and the hope that Sotrovimab will be effective against that. December looks extremely bullish for this trade. HC Wainwright & Co. has just reiterated coverage of Vir Biotechnology with a rating of Buy and set a new price target of $200.00 from $135.00 previously

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.